2 Hypergrowth Stocks That Are Screaming Buys in November
Growth investors have seen their fair share of bumps in the road the last few years, with some great businesses they follow being forced to navigate some real challenges. Several of these growth stocks managed their way through and are again delivering meaningful returns. If you have the investment capital and risk appetite to put cash into growth-oriented stocks, now might be a great time to put money into quality companies.
As you determine which ones to invest in, it’s important to only use cash that you won’t soon need for monthly financial obligations and to ensure you thoroughly understand any company you buy before you add it to your basket of investments.
Are You Missing The Morning Scoop? Breakfast News delivers it all in a quick, Foolish, and free daily newsletter. Sign Up For Free »
With those elements in mind, here are two top growth stocks to consider that look like screaming buys in November.
TransMedics Group (NASDAQ: TMDX) is a medical technology and devices company that focuses on organ transplant therapy for end-stage organ failure patients. The company was founded in 1998, and one of the achievements that the company is most known for is its Organ Care System (OCS). The TransMedics OCS is a device that enables the maintenance and preservation of donor organs from storing to transporting those organs to transplant patients.
The device can perform numerous functions, including imitating the temperature of the human body and transmitting nutrients to keep the donor organ healthy. Three types of organs can be preserved and stored in the TransMedics OCS — lungs, livers, and hearts. The OCS can maintain the health of organs outside of the human body for up to 24 hours in many cases.
With traditional cold storage methods that have historically been used to facilitate organ transplants, numerous complications regularly ensue ranging from ischemia to enhanced complications post-transplant. Ischemia is a common issue with organ transplants that occurs when insufficient blood flow to the donor organ causes damage to the tissue that can deteriorate further after the transplant.
With the TransMedics OCS, the risk of ischemia is greatly reduced, as is the risk of potential complications. Another integral aspect to TransMedic Group’s growth strategy is its logistics business, which even includes an air fleet that it uses to transport donor organs. TransMedics had 18 owned aircraft in its fleet at last count.
Management believes that the company is on track to achieve the goal of 10,000 OCS transplant cases per year in the U.S. by 2028. Total revenue in the third quarter of 2024 totaled approximately $109 million, a 64% increase from one year ago. Management noted that this revenue growth was driven by continued adoption of its OCS across all three organs as well as logistics revenue.
Leave a Reply